VACUNA DEL VIRUS DE LA HEPATITIS E Y PROCEDIMIENTO

• Main Authors: TWU, JR-SHIN, TAM, ALBERT W, KRAWCZYNSKI, KRZYSZTOF Z, REYES, GREGORY R, PURDY, MICHAEL A, BRADLEY, DANIEL W
• Format: Patent
• Language: Spanish
• Published: 16.12.2003
• Edition: 4
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

SON DESCUBIERTAS LAS COMPOSICIONES DE VACUNA DE ANTICUERPOS Y ANTIGENOS EFECTIVAS PARA PREVENIR LA INFECCION DEL VIRUS E DE HEPATITIS (HEV). LA COMPOSICION ANTIGENICA INCLUYE UN PEPTIDO CORRESPONDIENTE A LA CARBOXILO-TERMINAL DE LA PROTEINA DE LA CAPSIDA CODIFICADA POR LA SEGUNDA FASE DE LECTURA ABIERTA (2) DEL GENOMA DE HEV. LA COMPOSICION ES EFECTIVA EN PREVENIR LA INFECCION HEV DESPUES DE LA VACUNACION. LA COMPOSICION DE ANTICUERPO CONTIENE UN ANTICUERPO EFECTIVO PARA BLOQUEAR LA INFECCION DE HEV DE LOS HEPATOCITOS PRIMARIOS HUMANOS EN CULTIVO. Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame 2 of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.